AI Decision Support System for Detecting Skin Cancer in Primary Care A Multicenter Randomized Trial
Led by Linkoeping University · Updated on 2026-01-12
3000
Participants Needed
8
Research Sites
239 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an artificial intelligence AI decision support system called Dermalyser to help primary care physicians distinguish between skin cancer and benign skin lesions. This multicenter randomized controlled trial is conducted at about 30 primary care centers across Sweden, Germany, Scotland, the Netherlands, and Australia. The study aims to assess the accuracy, reliability, and clinical usefulness of Dermalyser in real clinical settings where most patients with skin lesions are managed.
Participants will be assessed at primary care centers randomized to either use Dermalyser as a complementary diagnostic tool or follow the standard clinical procedure without AI support. After reaching half of the planned enrollment, centers switch from one phase to the other. Physicians can choose to use Dermalyser when they find it indicated, but the final clinical decision about lesion management remains with the physician. Both groups will be followed for up to five years to track tumor diagnoses, proportions of skin cancer versus benign lesions, and related health outcomes.
During the study, participants will have their skin lesions evaluated according to either the AI-supported or standard procedure. The primary outcome measure is the proportion of skin cancers detected within six months of enrollment. Researchers will monitor morbidity and mortality related to skin cancer and compare differences between the groups. Participation may last up to five years with follow-up to assess diagnostic outcomes and safety. The study is sponsored by Linkping University.
CONDITIONS
Brief Title
Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care
Research Team
M
Magnus Falk, Professor
P
Panos Papachristou, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients attending a primary care facility to have one or more skin lesions checked for skin cancer, or presenting with one or more skin lesions raising suspicion of skin cancer
Willingness and ability to provide informed consent
You will not qualify if you...
Individuals with skin type V and VI according to the Fitzpatrick's scale (darker brown or black coloured skin)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 6 months from inclusion
Participants have their skin lesions assessed using standard clinical investigation procedures, with some assessments including AI decision support.
Visits as needed for lesion diagnosis within 6 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Phase 1 Study of Intratumoral ONM-501 Alone and with Cemiplimab for Advanced Solid Tumors and Lymphomas
Early Phase 0 Trial of Injecting Seasonal Flu Vaccine into Skin Cancer Tumors Before Mohs Surgery
Study of Daily 5% Niacinamide Cream to Prevent Skin Cancer in Adults Who Had Organ Transplants
Phase 1b2a Study to Evaluate Safety and Effectiveness of Oral Alintegimod with Ipilimumab Followed by Nivolumab in Adults with Advanced or Metastatic Solid Tumors
Study to Evaluate the Safety and Effectiveness of Intratumoral Alpha DaRT-224 Treatment for Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma
Study Evaluating Intratumoral Diffusing Alpha Radiation Emitters for Treating Malignant Skin,
Oral Mucosal, or Superficial Soft Tissue Tumors
Study of Intratumoral Diffusing Alpha Radiation Emitters DaRT for Treating Malignant Skin, Mucosal, or Superficial Soft Tissue Tumors
Evaluation of Intratumoral Alpha Radiation Device for Treating Malignant Skin Tumors Using DaRT Seeds
Study of Intratumoral Alpha Radiation Emitters with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Using ApolloVue S100 Full-field OCT Imaging to Diagnose Pigmented and Non-pigmented Skin Tumors
A Study of High-Resolution, Non-invasive Skin Imaging Technology
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Exploring the feasibility of an artificial intelligence based clinical decision support system for cutaneous melanoma detection in primary care - a mixed method study.
Jonatan Helenason, Christoffer Ekström, Magnus Falk...
Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial.
Panagiotis Papachristou, My Söderholm, Jon Pallon...